anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SAD Cohort 2 (FE study) is a two-sequence, two-period crossover study. A total of 14 healthy subjects will be randomized to two dosing sequences in a 1:1 ratio. Subjects in sequence 1 will receive a single dose of VG290131 (5 mg) or placebo under fasted condition in Period 1 and under fed condition in Period 2. Subjects in sequence 2 will be administered under fed condition in Period 1 and under fasted condition in Period 2. There will be a 7-day washout between the two dosing periods. Two sentinel subjects will be enrolled in the two dosing sequences of Period 1, respectively: one subject will be randomized to receive VG290131 (5 mg), and the other subject will be randomized to receive placebo. After the investigator reviews safety/tolerability information on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in that sequences will be randomized to receive VG290131 (n=4) and placebo (n=1). No sentinel subjects in Period 2.
Upper Crossed Syndrome is defined byJanda as the involvement of different muscles of skeletal system which leads to shortness and tightness of anterior and upper trunk or weakness of posterior part of skeletal muscles. Alteration of muscles activity such as facilitation of different muscles as levator scapula, sternocleidomastoid, pectoralis muscles and inhibition of cervical flexors, serratus anterior The muscular imbalance occurs because of weak/tight and tonic muscles. Neck pain is the most frequent problem in developed countries. The prevalence of neck pain is approximately 10-15%. Neck pain is the most common reason for patients visiting healthcare professionals. Poor posture typically causes upper cross syndrome (UCS), resulting in neck pain. This syndrome can cause dysfunctional tone in posture and muscular disparity of head, neck and shoulder region.
Cerium-doped alkaline-earth hafnium oxide scintillator compositions have at least one alkaline earth metal selected from the group consisting of Ba, Sr, Ca, and combinations thereof. The scintillator compositions can be formed into a shape having porosity less than about 0.05 percent for improved transparency. The alkaline earth metal can be partially substituted with divalent and/or trivalent ions other than cerium. Hafnium can be partially substituted with divalent, trivalent, and/or tetravalent ions. The scintillators are characterized by high light output, short decay time, and high radiation stopping power. The scintillators can be used as detector elements in PET systems.
People (importantly, of any age) who had respiratory symptoms (e.g. cough, sputum production, dyspnea, and/or exacerbation) with or without detectable structural (e.g. thoracic computed tomography (CT) emphysema, small and/or large airway impairments) and/or functional (e.g. low diffusion capacity for carbon monoxide (DLCO), hyperinflation, small airway obstruction, and/or accelerated FEV1 decline) abnormalities, in the absence of airflow limitation, and who might (or not) develop persistent airflow limitation (i.e. COPD) over time.
PROBLEM TO BE SOLVED: To obtain a perfume compsn. which has a flower-like aroma that reminds of muget, and has a high lingering scent by incorporating an 4- alkoxymethyl cyclohexyl methanol. SOLUTION: 1,4-Dimethylolcyclohexane is reacted with an alkyl, a cycloalkyl, or an alkenyl halide to etherify only one hydroxyl group. Thus, an 4- alkoxymethyl cyclohexyl methanol represented by the formula (wherein R represents a 1-10C alkyl group, a 3-10C cycloalkyl group, or a 2-10C alkenyl group) is synthesized. A blended perfume having a desired compsn. is blended with the 4-alkoxymethyl cyclohexyl methanol to obtain a contemplated aromatic perfume compsn. In the formula, pref., R represents a 1-5C alkyl group or a 3-5C alkenyl group with a methyl, ethyl, isopropyl, or allyl group being particularly pref.
The ear is the organ most susceptible to explosion overpressure, and cochlear injuries frequently occur after blast exposure. Blast exposure can lead to sensorineural hearing loss (SNHL), which is an irreversible hearing loss that negatively affects the quality of life. Detailed blast-induced cochlear pathologies, such as the loss of hair cells, spiral ganglion neurons, cochlear synapses, and disruption of stereocilia, have been previously documented. However, determining cochlear sensorineural deterioration after a blast injury is challenging because animals exposed to blast overpressure usually experience tympanic membrane perforation (TMP), which causes concurrent conductive hearing loss. To evaluate pure sensorineural cochlear dysfunction, we developed an experimental animal model of blast-induced cochlear injury using a laser-induced shock wave. This method avoids TMP and concomitant systemic injuries and reproduces the functional decline in the SNHL component in an energy-dependent manner after LISW exposure. This animal model could be a platform for elucidating the pathological mechanisms and exploring potential treatments for blast-induced cochlear dysfunction.
A telehealth care system is configured to provide a first service, in which the first service includes a first operation and a second operation. The telehealth care system includes a first host terminal, first electronic devices, and a central data center. The first electronic devices are configured to correspond to the first host terminal. The central data center is connected to the first host terminal and the first electronic devices. The first electronic devices are configured to perform the first operation via the central data center, and to perform the second operation via the first host terminal. The data processed by the first operation has a first data attribute, the data processed by the second operation has a second data attribute that is different from the first data attribute.
INTRODUCTION: Weight bias toward individuals with higher body weights permeates health care settings in the United States and has been associated with poor weight-related communication and quality of care as well as adverse health outcomes. However, there has been limited quantitative investigation into weight bias among perinatal care providers. Certified nurse-midwives (CNMs)/certified midwives (CMs) attend approximately 11% of all births in the United States. The aims of this study were to measure the direction and extent of weight bias among CNMs/CMs and compare their levels of weight bias to the US public and other health professionals.
METHODS: Through direct postcard distribution, social media accounts, professional networks, and email listservs, American Midwifery Certification Board (AMCB)-certified midwives were solicited to complete an online survey of their implicit weight bias using the Implicit Association Test and their explicit weight bias using the Antifat Attitudes Questionnaire, Fat Phobia Scale, and Preference for Thin People measure.
RESULTS: A total of 2257 midwives participated in the survey, yielding a completion rate of 17.7%. Participants were mostly White and female, with a median age of 46 years and 11 years since AMCB certification. More than 70% of midwives have some level of implicit weight bias, although to a lesser extent compared with previously published findings among the US public (P < .01) and other health professionals (P < .01). In a subsample comparison of female midwives to female physicians, implicit weight bias levels were similar (P > .05). Midwives also express explicit weight bias, but at lower levels than the US public and other health professionals (P < .05).
DISCUSSION: This study provides the first quantitative research documenting weight bias among a national US sample of perinatal care providers. Findings can inform educational efforts to mitigate weight bias in the perinatal care setting and decrease harm.
Various metabolites, including phytohormones, phytoalexins, and amino acids, take part in the plant immune system. Herein, we analyzed the effects of L-methionine (Met), a sulfur-containing amino acid, on the plant immune system in tomato. Treatment with low concentrations of Met enhanced the resistance of tomato to a broad range of diseases caused by the hemi-biotrophic bacterial pathogen Pseudomonas syringae pv. tomato (Pst) and the necrotrophic fungal pathogen Botrytis cinerea (Bc), although it did not induce the production of any antimicrobial substances against these pathogens in tomato leaf tissues. Analyses of gene expression and phytohormone accumulation indicated that Met treatment alone did not activate the defense signals mediated by salicylic acid, jasmonic acid, and ethylene. However, the salicylic acid-responsive defense gene and the jasmonic acid-responsive gene were induced more rapidly in Met-treated plants after infection with Pst and Bc, respectively. These findings suggest that low concentrations of Met have a priming effect on the phytohormone-mediated immune system in tomato.
Patients with ALS in the experimental, then sham arm will undergo an expiratory muscle strength training (EMST) session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 0% resistance.
(SEE INDICATIONS AND USAGE)

Initial: On the first day, either 100 mg b.i.d. for tablets or extended-release tablets, or ½ teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or extended-release tablets, or 50 mg (½ teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. Do not exceed 1200 mg daily. Maintenance: Control of pain can be maintained in most patients with 400 to 800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug.
Considering the widespread presence of pharmaceutical and personal care products (PPCPs) in the environment and their adverse health effects, human exposure to PPCPs has caused worldwide concern. However, there remains insufficient information on the exposure assessment of the Chinese population. Based on this, the exposure levels of 13 PPCPs in the urine samples of 986 Chinese adults were measured, aiming to provide information on the prevalence of PPCP occurrence and investigate potential correlations between PPCP exposure and obesity. Results showed that the detection rates of these compounds in urine ranged from 28.12 % to 98.58 %, with median concentrations ranging below the limit of detection to 10.58 ng mL-1. Methyl-paraben (MeP) was the most dominant paraben and had the highest urinary concentration (median = 10.12 ng mL-1), while 4-hydroxy-benzophenone (4-OH-BP) was the dominant benzophenone derivative (median = 0.22 ng mL-1). In antibacterials, the urinary concentration of triclosan (mean = 42.00 ng mL-1) was much higher than that of triclocarban (mean = 0.63 ng mL-1). PPCP concentrations were significantly associated with sex, age, body mass index, education level, and annual household income (p < 0.050). Regression analysis of dietary habits showed that seafood and tea consumption may be significant exposure sources of PPCP exposure (p < 0.050). Furthermore, individual exposure to MeP (odds ratio (OR) < 1, p = 0.002) and 4-OH-BP (OR < 1, p = 0.009) exhibited a significantly negative association with obesity in females. Also, analysis results from quantile g-computation and Bayesian kernel machine regression models demonstrated that an inverse correlation between PPCP mixture exposure and obesity was significant in females. This study reports the extensive prevalence of PPCP exposure among adults from China, and may provide crucial insights into PPCP exposure dynamics. More epidemiological studies are need in the future, with a thorough knowledge of PPCP exposure.
Personal distress associated with tic urges or inhibition and relief associated with tic production are defining features of the personal experience in Gilles de la Tourette syndrome (GTS). These affective phenomena have not been studied using fMRI, hindering our understanding of GTS pathophysiology and possible treatments. Here, we present a novel cross-sectional fMRI study designed to map tic-related phenomenology using distress and relief as predicting variables. We adopted a mental imagery approach and dissected the brain activity associated with different phases of tic behaviors, premonitory urges, and the ensuing tic execution or inhibition: these were compared with the mental simulation of "relaxed situations" and pre-determined stereotyped motor behaviors. We then explored whether the ensuing brain patterns correlated with the distress or relief perceived for the different phases of the tasks. Patients experienced a higher level of distress during the imagery of tic-triggering scenarios and no relief during tic inhibition. On the other hand, patients experienced significant relief during tic imagery. Distress during tic-triggering scenarios and relief during tic imagery were significantly correlated. The distress perceived during urges correlated with increased activation in cortical sensorimotor areas, suggesting a motor alarm. Conversely, relief during tic execution was positively associated with the activity of a subcortical network. The activity of the putamen was associated with both distress during urges and relief during tic execution. These findings highlight the importance of assessing the affective component of tic-related phenomenology. Subcortical structures may be causally involved in the affective component of tic pathophysiology, with the putamen playing a central role in both tic urge and generation. We believe that our results can be readily translated into clinical practice for the development of personalized treatment plans tailored to each patient's unique needs.
Ulcerative Colitis (UC) denotes a phenotype of chronic inflammatory bowel disease (IBD), where inflammation is localized to the colonic mucosa, and extends from the rectum proximally in varying extents. The disorder is thought to result from an inappropriate activation of the mucosal immune system by antigens derived from both the host epithelium and the enteric flora, in genetically susceptible individuals. UC is strikingly heterogeneous with respect to age of onset, anatomical extent and disease course, with some experiencing chronically active severe disease, while others have intermittent periods of clinical remission and disease exacerbation. Patients' therapeutic responses vary. The reasons underlying such variability are not well understood. Although it has been widely hypothesized that several genes may influence the development of UC, and modify its phenotypic expression and severity, to date there are few confirmed examples of such relationships.

It has been postulated that the 5-aminosalicylate drugs exert their anti-inflammatory effect locally at the intestinal mucosa. Mechanisms likely include inhibition of 5-lipoxygenase resulting in decreased production of leukotriene B4, scavenging of reactive oxygen metabolites, prevention of up-regulation of leukocyte adhesion molecules, and inhibition of Interleukin 1 (IL-1) synthesis. Though multiple studies have shown the efficacy of aminosalicylates in inducing and maintaining remission in adults with UC, there are few data in children.

Corticosteroids (CS) have been the mainstay of treatment of severe UC since efficacy was first demonstrated in the 1955 randomized controlled trial by Truelove and Witts. Recent practice guidelines developed in adults support their use because of rapid onset of action and significant efficacy though CS dependency is noted. Though no controlled data on their use have been reported in children they are frequently used in this population. A recent report from investigators leading the prospective Pediatric IBD Collaborative Research Group Registry described 97 subjects with a diagnosis of UC and a minimum of 1 year follow-up; 79% received CS. At diagnosis 81% of CS treated patients had moderate/severe disease, and 81% had pancolitis. Clinically inactive disease, determined by physician global assessment, was noted in 60% at 3 months following CS therapy, but by one year 45% were considered CS dependent despite the frequent use of immunomodulators (IM). Among those children with initially moderate to severe disease in clinical remission at 3 months, about two-thirds had stopped the CS by one year.
PURPOSE: To obtain a dental curable material comprising a filter in such a high content as to have viscosity not to be processed by a conventional method and to liquefy the material so as to be processed and used. CONSTITUTION: This curable material, especially a dental material comprises a binder and a filler having <50μm weight-average particle size in a high ratio. The material which is unusable for a specific use due to high viscosity caused by high ratio of the filler is treated by vibration having 1μm to 5mm amplitude and 20Hz to 20MHz frequency range and is liquefied in such a degree as to be used according to the standard. By this method, the producible and processible material, especially a highly packed (meth)acrylate can be produced. A multicomponent material is highly packed and mixed into a high-viscosity mixed product. Further in fixing an inlay, an onlay, an external laboratory dish and a material similar to it, vibration with a high frequency number is used to utilize a highly packed dental material.
The invention includes an implantable composition for management of pain in animals. The composition includes one or more active ingredients, a biocompatible polymer based drug delivery matrix, and other compounds to facilitate composition manufacture and durability. The composition disclosed herein is administered as a veterinary implant device. The implant is inserted subcutaneously into a patient and is designed to function in vivo for prolonged periods of time ranging from multiple weeks to months or even years. Accordingly, the composition must provide a constant release of one or more active ingredients over an extended period of time. To enable combination therapy for pain management, the composition may also include one or more layers of active ingredients seeded into one or more drug delivery systems. Multiple compositions having one or more layers loaded with different active ingredients may also be used in combination therapies.
High-altitude polycythemia (HAPC) affects individuals living at high altitudes, characterized by increased red blood cells (RBCs) production in response to hypoxic conditions. The exact mechanisms behind HAPC are not fully understood. We utilized a mouse model exposed to hypobaric hypoxia (HH), replicating the environmental conditions experienced at 6000 m above sea level, coupled with in vitro analysis of primary splenic macrophages under 1% O2 to investigate these mechanisms. Our findings indicate that HH significantly boosts erythropoiesis, leading to erythrocytosis and splenic changes, including initial contraction to splenomegaly over 14 days. A notable decrease in red pulp macrophages (RPMs) in the spleen, essential for RBCs processing, was observed, correlating with increased iron release and signs of ferroptosis. Prolonged exposure to hypoxia further exacerbated these effects, mirrored in human peripheral blood mononuclear cells. Single-cell sequencing showed a marked reduction in macrophage populations, affecting the spleen's ability to clear RBCs and contributing to splenomegaly. Our findings suggest splenic ferroptosis contributes to decreased RPMs, affecting erythrophagocytosis and potentially fostering continuous RBCs production in HAPC. These insights could guide the development of targeted therapies for HAPC, emphasizing the importance of splenic macrophages in disease pathology.
A method of orally administering measured doses of sugar into the bloodstream for controlling glucose levels, particularly for those individuals with diabetes or those who experience difficulty maintaining healthy blood sugar levels. The method comprises providing packets of orally ingestible strips of a disintegrating matrix containing a dose of sugar to supplement food intake between meals or to rapidly increase glucose levels in an emergency situation. Hypoglycemia is a condition of low blood sugar (glucose) levels in the bloodstream, which can have varying reactions on individuals ranging from mild to severe. The disclosed matrix and method rapidly introduces sugar into the blood stream for combating a hypoglycemic reaction. The strips are easily deployable and quickly dissolve once placed on the tongue and mixed with saliva. They can be packaged in a small, easy-to-dispense, and transportable case that allows rapid use when a sugar supplement is required.
In patients with type 1 diabetes mellitus, STEGLUJAN significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium glucose transporter 2 (SGLT2) inhibitors compared to patients who received placebo; this risk may be greater with higher doses. STEGLUJAN is not indicated for glycemic control in patients with type 1 diabetes mellitus.

Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors.

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.

Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected. Urinary glucose excretion persists for 4 days after discontinuing STEGLUJAN [see Clinical Pharmacology (12.2)]; however, there have been postmarketing reports of ketoacidosis and/or glucosuria lasting greater than 6 days and some up to 2 weeks after discontinuation of SGLT2 inhibitors.

Consider ketone monitoring in patients at risk for ketoacidosis if indicated by the clinical situation. Assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis. If ketoacidosis is suspected, discontinue STEGLUJAN, promptly evaluate, and treat ketoacidosis, if confirmed. Monitor patients for resolution of ketoacidosis before restarting STEGLUJAN.

Withhold STEGLUJAN, if possible, in temporary clinical situations that could predispose patients to ketoacidosis. Resume STEGLUJAN when the patient is clinically stable and has resumed oral intake [see Dosage and Administration (2.3)].

Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue STEGLUJAN and seek medical attention immediately if signs and symptoms occur.